Business, energy, technology, markets and global industry news from Business News Today

ArthemiR

PharmaDeviceNews ArthemiR
ARTHEx Biotech’s ATX-01 preclinical research examines whether systemic RNA therapy can reach the brain and improve DM1-related molecular and behavioral abnormalities. Representative image.
Pharma & Biotech

ARTHEx Biotech reports ATX-01 brain activity in preclinical myotonic dystrophy study

ARTHEx Biotech reports peer-reviewed preclinical evidence that ATX-01 reaches the brain and improves DM1-related behavior in mice.

Read More
Pharma & Biotech

Why ARTHEx Biotech’s ATX-01 update could reshape RNA-targeted therapy in myotonic dystrophy

Find out how ARTHEx Biotech’s ATX-01 data could reshape RNA-targeted therapy for myotonic dystrophy today!

Read More